---
source_pdf: "https://drive.google.com/file/d/18D8S_h9ha3GhUsJkQGtPW6_wwQD68qrH/view?usp=drivesdk"
drive_folder: "Portfolio/Prudentia"
type: portfolio
company: Prudentia
ingested: 2025-12-26
original_filename: "Prudentia Overview Deck.pdf"
---

> **Original:** [View Original PDF](https://drive.google.com/file/d/18D8S_h9ha3GhUsJkQGtPW6_wwQD68qrH/view?usp=drivesdk)

## Slide 1: Cover Page
# PRUDENTIA SCIENCES
AI platform to unlock clinical and commercial success of a drug

**Sadiqa Mahmood**
CEO and Founder
sm@prudentiasciences.com

Prepared for Virtua
Updated: July 22nd 2024

Confidential - Do not distribute
PRUDENTIA SCIENCES

## Slide 2: Our Team
# Our Team

**SADIQA MAHMOOD**
Founder and CEO

**JOHN REYNDERS, PhD**
Chief Technology Officer

**ANIL JINA, MD**
Chief Medical Officer

**PRANATHI VANGEEPURAM**
Head of Engineering

**DANIEL SAMAROV, PhD**
Head of Data Science

**ADHAM CHEBBANI**
Head of Sales

**Company Logos:**
* Health Catalyst
* Pfizer
* IQVIA
* PPD
* Arxspan
* moderna
* BROAD INSTITUTE
* sanofi
* Mass General Brigham
* ALEXION AstraZeneca Rare Disease
* HARVARD MEDICAL SCHOOL
* Dana-Farber Cancer Institute

Confidential - Do not distribute
PRUDENTIA SCIENCES
2

## Slide 3: Our Board Members and Advisors
# Our Board Members and Advisors

**WASIM MALIK (Investor & Broad Member)**
Managing Partner, Iaso Ventures
Chief Digital Strategist, Roivant ($7B IPO)
Director, Clinical Trial Network and Institute, Mass General Hospital

**TRAVIS MAY (Advisor)**
CEO, Shaper Capital
Co-Founder and CEO, Datavant ($7B M&A with Ciox)
Co-Founder and CEO, LiveRamp ($310M acquisition by Acxiom)

**JOE VON RICKENBAC (Advisor)**
Senior Advisor at General Atlantic
Co-Founder and CEO of PAREXEL ($8.5B acquisition by EQT and Goldman Sachs)
Co-Founder and CEO of Helio Vision (merged with Aldeyra, Inc. (NASDAQ: ALDX))

**Company Logos:**
* iaso VENTURES
* datavant
* parexel.
* ROIVANT SCIENCES

Confidential - Do not distribute
Our Team
SCIENCES
3

## Slide 4: Integrated Product Profile is the Foundation of Drug Asset Strategy
# Integrated Product Profile is the Foundation of Drug Asset Strategy

Integrated Product Profile (IPP) defines ideal drug profiles outlining the path to an approved drug label. It is used by various stakeholders throughout product lifecycle.

Current challenge is that building IPP is a manual and complex process to develop scientific, commercial and BD&L strategy.

**Stakeholders Chart Data:**

| Stakeholder Group          |
| :------------------------- |
| Discovery                  |
| Clinical Development & Operations |
| Medical Affair             |
| Regulatory Affairs         |
| Commercial                 |

**IPP Process Stages:**
* Ph I
* Ph II
* Ph III
* Ph IV
* IPP -> Label

Confidential - Do not distribute
PRUDENTIA SCIENCES
4

## Slide 5: Prudentia Sciences - AI platform to unlock clinical and commercial success of a drug
# Prudentia Sciences - AI platform to unlock clinical and commercial success of a drug

Design a data driven real-time Integrated Product Profile (IPP)

**Process Flow:**
1.  Assess Competitor Landscape
2.  Generate IPP using AI
3.  Test Scenarios for Clinical, Commercial and Regulatory Success

Confidential - Do not distribute
PRUDENTIA SCIENCES
5

## Slide 6: Massive Market Opportunity
# Massive Market Opportunity

Growing number of trial starts per year and increasing complexity of trials requires real-time Integrated Product Profile

Source: Citeline Trialtrove, Jan 2024; IQVIA Institute, Jan 2023

**Market Data:**
*   **$50B** Annual Global Clinical Trial Market
*   **5.8%** CAGR 2023 to 2030
*   **$18B** Spent on clinical trial design segment (TAM)
*   **$5.5B** IPP for every trial start (SAM)*
    *   *\*conservative pricing at $1M avg spend per trial per asset*

Confidential - Do not distribute
PRUDENTIA SCIENCES
6

## Slide 7: Prudentia Platform Users
# Prudentia Platform Users

**Prudentia Platform Users & Benefits:**

*   **Discovery**
    *   Data enabled drug candidate nomination & IND application
*   **Clinical Development & Ops**
    *   Clinical differentiation, study design & strategy
*   **Regulatory Affairs**
    *   Real time regulatory landscape and target label generation
*   **BD&L**
    *   Assess value of the asset and portfolio for dealmaking
*   **Commercial**
    *   Maximize market value and probability of reimbursement

Confidential - Do not distribute
PRUDENTIA SCIENCES
7

## Slide 8: Competitive Landscape
# Competitive Landscape

**Competitive Landscape Table:**

| Feature                            | Medidata Acorn AI | IQVIA Infosario | Certara Trial Simulator |
| :--------------------------------- | :---------------- | :-------------- | :---------------------- |
| SaaS Model                         | ●                 | ●               | ●                       |
| AI Platform with Active Learning   | ●                 | ●               | ●                       |
| Integrated Product Profile Generation | ●                 | ●               | ●                       |
| IPP Scenario Planning              | ●                 | ●               | ●                       |
| IPP Competitor Landscape Analysis  | ●                 | ●               | ●                       |

The following AI companies are not focused on IPP generation::
*   **Quant Health:** clinical endpoint simulation
*   **Yesop:** medical writing and clinical documentation
*   **Zephyr AI:** focused on clinical outcomes
*   **BenchSci:** drug discovery platform

Confidential - Do not distribute
PRUDENTIA SCIENCES
8

## Slide 9: Our Progress
# Our Progress

*   **MVP Launch**
    *   Platform available
*   **Data Partnerships**
    *   Access to proprietary information
*   **Clinically Trained AI**
    *   AI is clinical, regulatory and commercial informed
*   **Commercial Traction**
    *   Negotiating Pilot Projects

Confidential - Do not distribute
PRUDENTIA SCIENCES

## Slide 10: Vision – End to End Portfolio Strategy and Management
# Vision – End to End Portfolio Strategy and Management

**Process Flow:**
*   Discovery -> Commercialization

**Stages of Engagement:**
*   Engagement Throughout Product Life Cycle
*   Asset to Portfolio Strategy Design & Management
*   Clinical Development Plan

**Market Size:**
*   $30B - $50B TAM

Confidential - Do not distribute
PRUDENTIA SCIENCES
10